Logo do repositório
 
Publicação

COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

2025-05-21Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorDelaunay, Charlotte Laniece
dc.contributor.authorVerdasca, Nuno
dc.contributor.authorMonge, Susana
dc.contributor.authorDomegan, Lisa
dc.contributor.authorSève, Noémie
dc.contributor.authorBuda, Silke
dc.contributor.authorMeijer, Adam
dc.contributor.authorLucaccioni, Héloïse
dc.contributor.authorTorrijos, Miriam López
dc.contributor.authorMcKenna, Adele
dc.contributor.authorEnouf, Vincent
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorIn't Velt, Eline
dc.contributor.authorLaiglesia, Mª Ángel de Valcárcel
dc.contributor.authorBennett, Charlene
dc.contributor.authorMasse, Shirley
dc.contributor.authorErdwiens, Annika
dc.contributor.authorHooiveld, Mariette
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorTúri, Gergő
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorLazar, Mihaela
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorBorges, Vitor
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKissling, Esther
dc.contributor.authorEuropean primary care VE group
dc.date.accessioned2026-01-20T12:50:49Z
dc.date.available2026-01-20T12:50:49Z
dc.date.issued2025-05-21
dc.descriptionVEBIS Primary Care Vaccine Effectiveness Group: Portugal: Ausenda Machado, João Santos (Epidemiology Department, National Institute of Health Dr. Ricardo Jorge), Raquel Guiomar, Licínia Gomes, Camila Henriques and Daniela Dias (Infectious Disease Department, National Institute of Health Dr. Ricardo Jorge).
dc.description.abstractWe estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.eng
dc.description.sponsorshipFunding for this project was received from the European Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/019 ‘Vaccine effectiveness, burden and impact of COVID-19 and influenza’. For Spain (Navarre region): Instituto de Salud Carlos III PI22/00412.
dc.identifier.citationInfluenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111/irv.70120
dc.identifier.doi10.1111/irv.70120
dc.identifier.eissn1750-2659
dc.identifier.issn1750-2640
dc.identifier.pmid40395132
dc.identifier.urihttp://hdl.handle.net/10400.18/10721
dc.language.isoeng
dc.peerreviewedyes
dc.publisherWiley
dc.relation.hasversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.70120
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID‐19
dc.subjectSARS‐CoV‐2
dc.subjectVaccine Effectiveness
dc.subjectEurope
dc.subjectInfecções Respiratórias
dc.subjectCuidados de Saúde
dc.titleCOVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Networkeng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue5
oaire.citation.startPagee70120
oaire.citation.titleInfluenza and Other Respiratory Viruses
oaire.citation.volume19
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Influenza Resp Viruses - 2025 - Laniece Delaunay - COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic.pdf
Tamanho:
216.07 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DDI - Artigos em revistas internacionais
DEP - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais